Operating within a highly regulated, innovation-driven global market, the pharmaceutical sector demands precision, compliance and operational excellence at every stage. With over 20 years’ experience in pharmaceutical project delivery, Engenda supports clients across the full life sciences spectrum – from primary and secondary manufacturing through to specialist equipment manufacturers and medical device organisations.
We work across GMP production facilities, research laboratories and large-scale, campus-style life sciences environments.
With strong regulatory knowledge and a deep understanding of industry safety standards, Engenda delivers high-quality, compliant engineering solutions with a focus on safety, reliability and performance. Our integrated service offering spans the full project lifecycle – from concept and design through to fabrication, installation, commissioning and ongoing maintenance.
Core Markets:
Primary Pharmaceuticals
Secondary Pharmaceuticals
Biotech
Medical Devices
We support manufacturers of sterile salts, corticosteroids, opiate alkaloids, denatonium, biologics, bio-conjugates and a wide range of specialist medical applications.
Capability and Delivery
Engenda has extensive experience delivering EPC, Design & Build and fully turnkey solutions across a broad range of specialist pharmaceutical equipment and processes, including:
Fast fill and finish lines
Packaging and blister systems
GMP production environments
Agitators and process vessels
Bulk storage systems
Boilers, blowers and utilities infrastructure
This includes new-build facilities, upgrades and the relocation of complete production units.
Services provided to the wider chemical and process industry include:
The global pharmaceutical market has continued its strong growth trajectory and is now valued at approximately $1.7–1.8 trillion in 2025, having expanded significantly over the past two decades. [statista.com]
Looking ahead, the market is forecast to grow steadily, reaching over $1.8 trillion in 2026 and exceeding $2–3 trillion by the early 2030s, driven by innovation, demographic trends and rising global healthcare demand.
Key global growth drivers include:
Ageing populations and increased prevalence of chronic disease
Growth in biologics, gene therapies and personalised medicine
Advances in AI-enabled drug discovery and development
Expanding access to healthcare in emerging markets
High-value therapy areas such as oncology, immunology and metabolic diseases continue to dominate investment and innovation pipelines.
UK Market Context
The UK remains a leading global hub for life sciences, supported by strong research capability, investment and infrastructure:
The UK life sciences sector employs approximately 360,000 people [gov.uk]
Generates around £146.9 billion in annual turnover
Pharmaceutical manufacturing contributes approximately £17.6 billion in GVA [abpi.org.uk]
The sector invests heavily in innovation, with £9.3 billion in R&D spending (2024)
The UK continues to attract significant investment, particularly in:
Biotech and advanced therapies
AI-driven drug discovery
Clinical trials and R&D infrastructure
Industry Trends and Challenges
The pharmaceutical sector is undergoing rapid transformation, shaped by: